

Special Issue

Antibody Drug Conjugates: Unlocking the Future of Immunotherapies

Message from the Guest Editors

Antibody Drug Conjugates (ADC) are quintessential example of advanced biopharmaceutical therapies. These targeted nanomedicines use the specificity of monoclonal antibodies to guide highly potent cytotoxic payloads to specific target cell. The resulting ADCs have a broader therapeutic window than their potent payloads while sparing healthy cells. Currently there are 12 ADCs approved for the treatment of haematological and solid tumour malignancies. Despite growing interest in this complex biopharmaceutical modality challenges remain to improve ADC quality, safety, and efficacy. This Special Issue of *Pharmaceutics* will focus on recent advances in ADC development from ADC design including identification of new targets, antibody selection, development of new conjugation and linker chemistry technologies, novel payloads and mechanism of action, ADC characterisation platforms, to ADC preclinical characterisation including pharmacokinetics, pharmacodynamics, biodistribution, toxicity and efficacy studies and clinical studies looking at oncology and non-oncology applications.

Guest Editors

Prof. Dr. Deyarina Gonzalez

Medical School, Swansea University, Singleton Park, Swansea SA2 8PP, UK

Prof. Dr. R. Steven Conlan

Medical School, Swansea University, Singleton Park, Swansea SA2 8PP, UK

Deadline for manuscript submissions

closed (30 June 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/103624

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).